PYXS vs. RANI, MGNX, ADCT, ACET, STTK, ABVX, SPRY, IMNM, IRON, and CNTA
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Rani Therapeutics (RANI), MacroGenics (MGNX), ADC Therapeutics (ADCT), Adicet Bio (ACET), Shattuck Labs (STTK), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Disc Medicine (IRON), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking.
Rani Therapeutics has higher revenue and earnings than Pyxis Oncology. Rani Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Rani Therapeutics received 3 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 76.67% of users gave Rani Therapeutics an outperform vote.
Pyxis Oncology's return on equity of -38.99% beat Rani Therapeutics' return on equity.
Pyxis Oncology has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 9.3% of Pyxis Oncology shares are held by insiders. Comparatively, 53.3% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Pyxis Oncology had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Pyxis Oncology and 3 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 1.18 beat Pyxis Oncology's score of 0.82 indicating that Rani Therapeutics is being referred to more favorably in the news media.
Pyxis Oncology presently has a consensus target price of $8.80, suggesting a potential upside of 136.56%. Rani Therapeutics has a consensus target price of $12.20, suggesting a potential upside of 138.28%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Pyxis Oncology.
Summary
Pyxis Oncology beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
